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ABSTRACT
Here, we performed a systematic analysis to discover new biomarkers of overall 
survival and tumor progression in ovarian cancer patients. More specifically, we 
determined whether nuclear-encoded mitochondrial genes related to mitochondrial 
biogenesis and function are effective in predicting clinical outcome in ovarian cancer. 
As a consequence, we are able to provide in silico validation of the prognostic value of 
these mitochondrial markers, in a well-defined population of ovarian cancer patients. 
Towards this end, we used a group of N=111 ovarian cancer patients (serous type; 
stage III), with optimal de-bulking. Importantly, in this group of cancer patients, 
CA125 and PCNA (conventional markers) were associated with poor overall survival, 
as would be expected. Using this approach, we identified >100 new individual 
mitochondrial gene probes that effectively predicted significantly reduced overall 
survival, with hazard-ratios (HR) of up to 3.68 (p < 9.8e-05). These mitochondrial 
mRNA transcripts included membrane proteins, chaperones, anti-oxidant enzymes, 
as well as mitochondrial ribosomal proteins (MRPs) and key members of the OXPHOS 
(I-V) complexes. Based on this bioinformatics analysis and in silico validation, we 
conclude that mitochondrial biogenesis and OXPHOS should both be considered as 
new therapeutic targets, for the more effective treatment of human ovarian cancers. 
The mitochondrial biomarkers that we have identified could also be employed as new 
companion diagnostics to assist oncologists in: i) more accurately predicting clinical 
outcomes and ii) improving the response to therapy, in ovarian cancer patients. 
INTRODUCTION
Drug-resistance dramatically limits the effectiveness 
of most cancer therapies, and especially for ovarian 
cancer patients [1, 2]. As such, treatment failure remains 
a significant barrier to successful cancer therapy and 
precision medicine [3, 4]. As a result, new biomarkers are 
urgently required for the treatment stratification of ovarian 
cancer patients, into different risk sub-groups at diagnosis 
(high-risk versus low-risk) [5]. 
In this report, we tested the hypothesis that 
mitochondrial markers might have prognostic value for 
the identification of high-risk ovarian cancer patients, with 
increased progression and poor overall survival. For this 
purpose, we used a data-mining and informatics strategy 
to determine the potential effectiveness of mitochondrial 
gene transcripts, in predicting clinical outcome. 
Our results indicate that >100 mitochondrial 
gene probes can be used individually or in various 
combinations, to predict poor overall survival in ovarian 
cancer patients. Based on these current findings, we 
speculate that mitochondrial biogenesis and/or OXPHOS 
could be targeted therapeutically to prevent ovarian cancer 
recurrence and extend overall survival. 
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RESULTS
Prognostic value of conventional markers (CA125 
and PCNA) in the patient population
To identify novel biomarkers for ovarian cancers, 
we employed publically available transcriptional profiling 
data from the tumors of patients with serous ovarian 
cancer (stage III), with optimal de-bulking, low CA125 
levels at diagnosis, and 5-years of follow-up data (Figure 
1). 
First, we assessed the prognostic value of CA125 
in this context. The results of this analysis are shown in 
Figure 2 and Table 1. Note that the hazard-ratio (HR) for 
CA125 was 2.29 (p = 0.005) for overall survival (OS). As 
proliferative markers are often used as key endpoints in 
Phase II clinical trials, we next assessed the prognostic 
value of Ki67 and PCNA. Figure 2 and Table 2 both show 
the prognostic value of these markers. The results with 
Ki67 were not significant, but PCNA showed a hazard-
ratio of 2.85 (p = 0.00025). Similarly, we determined the 
utility of macrophage-specific markers of inflammation. 
However, Table 3 shows that that CD68 and CD163 did 
not show significant prognostic value.
Thus, a subset of conventional markers (CA125 and 
PCNA) can be used to predict overall survival in ovarian 
cancer patients.
Prognostic value of individual mitochondrial 
markers
Our hypothesis is that increased mitochondrial 
biogenesis drives poor overall survival in ovarian 
cancer patients. To directly test this hypothesis, we 
next determined the prognostic value of a series of 
mitochondrial markers. 
Firstly, we interrogated the utility of the behavior of 
mitochondrial chaperones and mitochondrial membrane 
proteins. Table 4 and Figure 3A both show that SLC25A5 
and TIMM10 have significant prognostic value, with 
hazard-ratios of 2.67 and 2.63, respectively. Other 
members of the SLC25A, TIMM, TOMM and VDAC 
families also had prognostic value. Mitochondrial-related 
antioxidant proteins (NQO1 and SOD2), as well as 
mitochondrial creatine kinase, also had significant value 
(summarized in Table 4 and Figure 3B). 
Next, we carefully examined the prognostic 
value of mitochondrial ribosomal proteins (MRPs). 
They functionally control the biosynthesis of essential 
components of the OXPHOS complexes, driving 
mitochondrial biogenesis (Table 5). Ten members of the 
large subunit (MRPLs) showed significant prognostic 
value, with hazard-ratios between 3.56 and 1.90. 
Interestingly, MRPL49 had the best prognostic value. 
Eleven different members of the small subunit (MRPSs) 
showed significant prognostic value, with hazard-ratios 
Figure 1: Summary illustrating our systematic approach to ovarian cancer biomarker discovery. For this analysis, we 
chose to focus on serous ovarian cancer patients, with optimal de-bulking, and 5-years of follow-up data (N = 111). In this context, we 
evaluated the prognostic value of mitochondrial markers for predicting overall survival (OS), progression-free survival (PFS) and post-
progression survival (PPS). 
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Figure 2: Traditional markers (CA125 and PCNA) predict poor overall survival in ovarian cancer patients. We assessed 
the predictive value of CA125 and PCNA in N = 111 ovarian cancer patients, with optimal de-bulking. Note that high transcript levels of 
CA125 and PCNA are associated with significantly reduced overall survival. 
Table 1: Prognostic value of CA125 in ovarian cancer
Table 2: Prognostic value of KI67 in ovarian cancer
Table 3: Prognostic value of PCNA and markers of inflammation in ovarian cancer
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Figure 4: Mitochondrial ribosomal proteins (MRPs) are associated with poor clinical outcome in ovarian cancer 
patients. A. Note that high transcript levels of MRPL49 and MRPL34 predict significantly reduced overall survival. B. Similarly, high 
transcript levels of MRPS14 and MRPS12 predict significantly reduced overall survival. 
Figure 3: Mitochondrial membrane proteins and NQO1 are associated with poor clinical outcome in ovarian cancer 
patients. A. Note that that high transcript levels of SLC25A5 and TIMM10 are associated with significantly reduced overall survival. B. 
Note that that high transcript levels of NQO1 are associated with significantly reduced overall survival.
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Figure 6: Mitochondrial complex III and IV proteins are associated with poor clinical outcome in ovarian cancer 
patients. A. Note that high levels of UQCRFS1 and UQCR7 predict significantly reduced overall survival. B. Similarly, high levels of 
COX6B and COX17 predict significantly reduced overall survival. 
Figure 5: Mitochondrial complex I and II proteins are associated with poor clinical outcome in ovarian cancer 
patients. A. Note that high levels of NDUFA3 and NDUFB11 predict significantly reduced overall survival. B. Similarly, high levels of 
SDHC predict significantly reduced overall survival. 
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between 2.90 and 1.88. In summary, twenty-one different 
MRPs all predicted poor overall survival. Kaplan-Meier 
curves for representative examples are shown in Figure 4, 
panels A & B.
Similarly, we also determined the prognostic 
value of key components of the OXPHOS complex. 
These results are summarized in Table 6. Surprisingly, 
52 different gene probes for the OXPHOS complexes 
showed hazard-ratios between 3.68 and 1.76. Complex I 
had the most subunits with significant prognostic value 
(21 in total). However, UQCRFS1 (complex III) had the 
best individual prognostic value (HR = 3.68; p = 9.8e-05). 
NDUFA3 (complex I) also showed significant prognostic 
value (HR = 3.55; p = 2.3e-05). Kaplan-Meier curves for 
members of complex I and II are shown in Figure 5A & 
5B, while results with members of complex III and IV are 
shown in Figure 6A & 6B. Results with complex V are 
shown in Figure 7.
Three new mitochondrial gene signatures for 
predicting overall survival, recurrence and the 
response to therapy
To significantly amplify the prognostic power of 
these unique mitochondrial markers, we then combined 
the most promising markers and to derive three new 
mitochondrial gene signatures. 
Ov-Mito-Signature-1 contains 2 genes (MRPL49/
UQCRFS1). One component is an MRPL, while the 
other is part of the OXPHOS machinery (complex III). 
Ov-Mito-Signature-2 also consists of 2 genes (NDUFA3/
UQCRFS1). Both components are part of the OXPHOS 
machinery (complexes I and III). In addition, Ov-Mito-
Signature-3 consists of 3 genes (NDUFA3/UQCRFS1/
PCNA), namely 2 mitochondrial genes and a proliferative 
marker (PCNA) (See Tables 7-9). K-M curves for these 
three signatures are shown in Figures 8-14.
Table 4: Prognostic value of chaperones, mitochondrial membrane proteins, anti-oxidants and 
creatine kinase
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Figure 7: Mitochondrial complex V proteins are associated with poor clinical outcome in ovarian cancer patients. Note 
that high levels of ATP5C and ATP5G3 predict significantly reduced overall survival. 
Table 5: Prognostic value of mitochondrial ribosomal proteins
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Table 6: Prognostic value of mitochondrial OXPHOS complexes
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Figure 8: Ov-Mito-Signature 1 predicts patient outcome in ovarian cancer patients. Note that high levels of Ov-Mito-
Signature 1 (MRPL49/UQCRFS1) effectively predicts overall survival (OS), progression-free survival (PFS) and post-progression survival 
(PPS). OS and PFS are shown in panel A. PPS is shown in panel B. 
Table 7: Prognostic value of ovarian mitochondrial signature 1
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Figure 10: Ov-Mito-Signature 2 predicts patient outcome in ovarian cancer patients. Note that high levels of Ov-Mito-
Signature 2 (NDUFA3/UQCRFS1) effectively predicts overall survival (OS), progression-free survival (PFS) and post-progression survival 
(PPS). OS and PFS are shown in panel A. PPS is shown in panel B. 
Figure 9: Ov-Mito-Signature 1 predicts the response to therapy in ovarian cancer patients. Note that high levels of Ov-
Mito-Signature 1 (MRPL49/UQCRFS1) effectively predicts drug-resistance and treatment failure, illustrated here as overall survival. 
Results with Platin and Taxol therapy (Rx) are shown.
Table 8: Prognostic value of ovarian mitochondrial signature 2
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Importantly, Ov-Mito-Signature-1 yielded a 
significantly improved hazard-ratio for overall survival of 
4.59 (p = 3.1e-05) (Table 7 and Figure 8A, left). It was 
also highly predictive for progression-free survival (Figure 
8A, right) and post-progression survival (Figure 8B), in 
the same group of patients. In addition, it effectively 
predicted the response to chemotherapy and treatment 
failure, in patients that received “Platin-derivatives” or 
“Taxol” (Figure 9).
Similarly, Ov-Mito-Signature-2 showed a hazard-
ratio for overall survival of 5.03 (p = 1.2e-05) (Table 8 
and Figure 10A, left). Ov-Mito-Signature-2 was also 
highly predictive for progression-free survival (Figure 
10A, right) and post-progression survival (Figure 10B). 
Also, it effectively predicted the response to chemotherapy 
(Figure 11). 
As such, both of these Ov-Mito-Signature(s) were 
a dramatic improvement over individual mitochondrial 
biomarkers, as well as CA125 and PCNA (Tables 1 & 3; 
Figure 2). 
To further improve the predictive value of Ov-
Mito-Signature-2, we next added the proliferative marker 
PCNA, to create Ov-Mito-Signature-3. The robust 
nature of Ov-Mito-Signature-3 is highlighted in Table 9 
Figure 12: Ov-Mito-Signature 3 predicts patient outcome in ovarian cancer patients. Note that high levels of Ov-Mito-
Signature 3 (NDUFA3/UQCRFS1/PCNA) effectively predicts overall survival (OS), and progression-free survival (PFS).
Figure 11: Ov-Mito-Signature 2 predicts the response to therapy in ovarian cancer patients. Note that high levels of Ov-
Mito-Signature 2 (NDUFA3/UQCRFS1) effectively predicts drug-resistance and treatment failure, illustrated here as overall survival. 
Results with Platin and Taxol therapy (Rx) are shown. 
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and Figures 12-14, which shows a hazard-ratio of 5.63 
(p = 7.6e-06). Ov-Mito-Signature-3 was also the most 
effective in predicting the response to therapy (Figure 13). 
Importantly, Ov-Mito-Signature-3 retained its prognostic 
value in a larger group of serous ovarian cancer patients 
(N = 442), without restricting our analysis to patients with 
low serum CA125 levels (Figure 14). 
DISCUSSION
Understanding CSCs, telomerase and 
mitochondrial activity: targeting ovarian cancer 
with doxycycline and/or palbociclib
The exact functional role of telomerase activity 
in ovarian cancer stem cell (CSC) propagation remains 
largely unknown. Recently, to address this issue, we 
indirectly monitored telomerase activity, by linking the 
hTERT-promoter to eGFP [6, 7]. Using SKOV3 ovarian 
cancer cells, stably-transfected with the hTERT-GFP 
reporter, we then used GFP-fluorescence to fractionate 
these cell lines into GFP-high and GFP-low populations. 
We functionally compared the phenotype of these GFP-
high and GFP-low cell sub-populations. Importantly, we 
showed that ovarian cancer cells with higher telomerase 
activity (GFP-high) are energetically-activated, with 
increased mitochondrial OXPHOS and glycolysis [6]. 
This was confirmed by unbiased label-free proteomics 
analysis. A sub-population of SKOV3 cells with high 
telomerase activity showed i) increased “stemness” 
(3D-spheroid formation) and ii) enhanced cell migration 
(Boyden-chamber assay). These cellular phenotypes 
were halted by inhibitors of energy-metabolism, targeting 
either OXPHOS or glycolysis, or by using doxycycline, a 
clinically-approved antibiotic, that inhibits mitochondrial 
biogenesis [6, 7]. 
Telomerase activity also determined the ability of 
hTERT-high ovarian CSCs to proliferate, as determined 
by monitoring DNA-synthesis. Use of Palbociclib, a 
CDK4/6 inhibitor (an FDA-approved drug) specifically 
blocked ovarian CSC propagation, with an IC-50 of ~100 
nM [6]. Thus, telomerase-high ovarian CSCs are the most 
energetically-activated, migratory and proliferative cell 
sub-population [6]. These findings suggest a mechanistic 
Figure 13: Ov-Mito-Signature 3 predicts the response to therapy in ovarian cancer patients. Note that high levels of 
Ov-Mito-Signature 3 (NDUFA3/UQCRFS1/PCNA) effectively predicts drug-resistance and treatment failure, illustrated here as overall 
survival. Results with Platin and Taxol therapy (Rx) are shown. 
Table 9: Prognostic value of ovarian mitochondrial signature 3
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interpretation for why long telomere length (a specific 
marker of high telomerase activity) is strictly correlated 
with metastasis disease progression and poor outcome in 
ovarian tumors and other cancer types [8, 9]. 
As such, elevated telomerase activity may “fuel” the 
propagation of ovarian CSCs
by activating mitochondrial biogenesis, ultimately 
leading to poor clinical outcome. These observations 
may help explain why combining mitochondrial markers, 
together with the proliferation marker PCNA, so 
significantly increased the prognostic value of this Ov-
Mito-Signature. 
Employing mitochondrial markers and mito-
signatures, as companion diagnostics for 
treatment stratification: implications for drug re-
purposing
In support of our current hypothesis, integrating 
telomerase activity with increased mitochondrial function, 
we demonstrate that a sub-set of mitochondrial gene 
transcripts are able to predict survival in serous ovarian 
cancer patients, with optimal de-bulking. As such, these 
particular mitochondrial markers could ultimately be used 
to select high-risk ovarian cancer patients at diagnosis, up 
to 5 years in advance, for close monitoring. As such, our 
results provide an excellent justification for the therapeutic 
targeting of mitochondria in ovarian cancer cells, to 
improve patient survival. 
In this new paradigm, high-risk patients would 
be identified at diagnosis by the over-expression of 
mitochondrial mRNA transcripts in their ovarian tumors 
(Figure 15). As a consequence, these patients could 
then be treated with certain FDA-approved drugs (e.g., 
Doxycycline or Palbociclib; together with the standard of 
care), to improve overall survival. These therapeutics have 
been previously documented to halt the proliferation of the 
ovarian CSC population [6]. 
FDA-approved antibiotics can safely prevent 
mitochondrial biogenesis and/or OXPHOS as a 
manageable, off-target, “side-effect” [6, 7, 10-16]. These 
antibiotics include the tetracyclines, the erythromycins, as 
well as pyrvinium pamoate, atovaquone, and bedaquiline 
[10, 11, 13, 14]. For example, the new mitochondrial 
markers and Mito-Signatures we have discovered, could 
be used as companion diagnostics, for re-purposing these 
FDA-approved drugs as novel anti-cancer agents. More 
specifically, this would facilitate the ability of medical 
oncologists to identify the correct patient sub-population 
for new phase II clinical trials for drug re-purposing/re-
positioning in serous ovarian patients, as an add on to 
conventional chemo-therapy (e.g., platins and taxol). 
Mitochondrial markers and mito-signatures: 
implications for new drug discovery
The three new Mito-Signatures that we developed 
may also be useful for selecting new “druggable” targets 
for new drug development, to prevent treatment failure 
and improve overall survival. As a consequence of our 
K-M analyses, the mitochondrial ribosome would be an 
attractive new target for developing novel inhibitors of 
mitochondrial protein translation in cancer cells; similarly, 
mitochondrial chaperones, the OXPHOS complexes and 
the mitochondrial ATP-synthase may also be suitable drug 
Figure 15: Ovarian cancer: mitochondrial-based 
companion diagnostics for personalized cancer 
therapy. In this diagram, mitochondrial-based diagnostics 
would be used to separate ovarian cancer patients into higher-
risk and lower-risk groups. Then, patients with high levels of 
mitochondrial markers in their primary tumor (“bad prognosis”) 
would be treated with mitochondrial-based therapies (such as 
“Doxycycline”), as an add-on to the standard of care, to prevent 
tumor progression and increase overall survival.
Figure 14: Ov-Mito-Signature 3 predicts patient 
outcome in ovarian cancer patients. Note that high 
levels of Ov-Mito-Signature 3 (NDUFA3/UQCRFS1/PCNA) 
effectively predicts overall survival (OS), in a larger group of 
ovarian cancer patients (N = 442). 
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targets. Multiple members of these multi-subunit protein 
complexes show significant prognostic value, suggesting 
that modulation of their intrinsic activity may provide 
therapeutic benefits. Targeting of these large complexes 
would be predicted to suppress tumor recurrence and 
prevent disease progression in these serous ovarian cancer 
patients. 
In addition, such mitochondrial markers could also 
be employed as companion diagnostics for novel therapies 
targeting either mitochondria or telomerase (hTERT) and/
or cell proliferation, to select the high-risk sub-population 
of ovarian cancer patients, resulting in the necessary 
treatment stratification. In direct support of this assertion, 
we showed here that three different Mito-Signature(s) 
could be used to successfully identify the sub-population 
of high-risk ovarian cancer patients that failed “platin” 
or “taxol” based therapies. These results indicate that 
mitochondrial markers could be used to monitor and/or 
predict the response to therapy, specifically identifying 
patients at high-risk for treatment failure at diagnosis, up 
to 5 years in advance, even before therapy is initiated. 
METHOD OF ANALYSIS
Kaplan-Meier (K-M) Analyses. To perform K-M 
analysis on nuclear mitochondrial gene transcripts, we 
used an open-access online survival analysis tool to 
interrogate publically available microarray data from up 
to 1,435 ovarian cancer patients [5]. This allowed us to 
determine their overall prognostic value. For this purpose, 
we primarily analyzed 5-year follow-up data from serous 
ovarian cancer patients (stage III) that had optimal de-
bulking (N = 111). Biased array data were excluded from 
the analysis. This allowed us to identify >100 nuclear 
mitochondrial gene probes, with significant prognostic 
value. Hazard-ratios for overall survival (OS), progression 
free survival (PFS; recurrence) and post-progression 
survival (PPS) were calculated, at the best auto-selected 
cut-off, and p-values were calculated using the logrank 
test and plotted in R [5]. K-M curves were also generated 
online using the K-M-plotter (as high-resolution TIFF 
files), using univariate analysis: 
http://kmplot.com/analysis/index.
php?p=service&cancer=ovar.
This allowed us to directly perform in silico 
validation of these mitochondrial biomarker candidates. 
The 2012 version of the database was originally utilized 
for all these analyses; however, virtually identical results 
were also obtained with the 2015 and 2017 versions.
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